Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refrac

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Related Keywords

Houston , Texas , United States , America , American , Vincerx Pharma , Acerta Pharma , Pepromene Bio , Michael Wang , Biopharma Cayman , Ideology Health , Life Sciences , Oncologist Network , University Of Texas Md Anderson Cancer Center , Leukemia Lymphoma Society , Genentech , Amphista Therapeutics , Moffitt Cancer Center , Bristol Myers Squibb , Department Of Lymphoma Myeloma , Practice Point Communications , Milken Institute , Eastern Virginia Medical School , Deciphera Pharmaceuticals , International Conference On Malignant Lymphoma , Oncology Specialty Group , Astrazeneca , Annual International Conference , Cancer Center , Amphista Therapeutics Limited , Kite Pharma , Lymphoma Society , Miltenyi Biomedicine , Oncternal Therapeutics , Bantam Pharmaceutical , Chinese American Hematologist , Meeting Minds Experts , Nurix Therapeutics , Physician Education Resource , Juno Therapeutics , Loxo Oncology , Molecular Templates ,